Aranzazu Fernández-Martínez

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini, Núria Chic, Fara Brasó‐Maristany et al. · npj Breast Cancer · 2021 · 691 citations · Full text

Medicine, Cancer Biology, Oncology +10

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

Aleix Prat, Aranzazu Fernández-Martínez, Katherine A. Hoadley et al. · BMC Medicine · 2015 · 161 citations · Full text

Medicine, Biostatistics, Oncology +15

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

Aranzazu Fernández-Martínez, Ian E. Krop, David W. Hillman et al. · Journal of Clinical Oncology · 2020 · 127 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer

Aranzazu Fernández-Martínez, Tomás Pascual, Baljit Singh et al. · JAMA Oncology · 2023 · 75 citations · Full text

Medicine, Cancer Biology, Oncology +17

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

Guillermo Villacampa, Nadine Tung, Sònia Pernas et al. · Annals of Oncology · 2023 · 53 citations · Full text

Medicine, Oncology, Pathology +15